MedTrace Logo

Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

NCT02643667 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-01-08

Study results available
· View outcomes & findings →

Summary

30-40% of patients who undergo radical prostatetecomy (RP) with curative intent for their localized prostate cancer experience relapse of their disease. Thus, improved therapeutic approaches are needed in this patient population. Enhancing the patient's anti-tumor immune response prior to surgery may improve long-term outcomes following RP

Conditions

Interventions

DRUG

Ibrutinib

-Ibrutinib will be supplied by Pharmacyclics Inc.

PROCEDURE

Radical prostatectomy

-Standard of care

Sponsors & Collaborators

  • Pharmacyclics LLC.

    collaborator INDUSTRY

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Russell K Pachynski, M.D. · Washington University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2023-04-12
Completion
2023-04-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02643667 on ClinicalTrials.gov